Artículos de revistas
Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia
Fecha
2006-11-01Registro en:
Quimica Nova, v. 29, n. 6, p. 1307-1316, 2006.
0100-4042
1678-7064
10.1590/S0100-40422006000600028
S0100-40422006000600028
WOS:000242341600028
2-s2.0-33845716527
2-s2.0-33845716527.pdf
9734333607975413
0000-0003-4141-0455
Autor
Universidade Estadual Paulista (Unesp)
Institución
Resumen
Strategies that promote selective activation of prodrugs by enzymes can be divided into two major classes: 1) deliver of a monoclonal antibody-enzyme immunoconjugate that can recognize a specific antigen and promote the prodrug to a citotoxic drug, with a high selectivity for the target cells, and 2) selective gene delivery encoding an enzyme that can promote the prodrug to a citotoxic drug for the target cells. In this article are discussed ADEPT (antibody-directed enzyme prodrug therapy), GDEPT (gene-directed enzyme prodrug therapy), VDEPT (virus-directed enzyme prodrug therapy), GPAT (genetic prodrug activation therapy) and PDEPT (polymer-directed enzyme prodrug therapy) approaches, their clinical trials, advantages, disadvantages and perspectives.